A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Phase 2CompletedNCT00486200

Astellas Pharma Inc695 enrolled

Overview

A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

695

Conditions

Herpes Genitalis

Interventions

ASP2151DRUG

Oral administration.

valacyclovirDRUG

Oral administration of active comparator.

PlaceboDRUG

Oral administration of placebo.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject has a history of genital HSV documented by laboratory testing at screening * Subject has experienced 4 or more episodes of genital herpes during the past 12 months Exclusion Criteria: * Subject is immunocompromised

Locations (25)

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Phoenix, Arizona, United States

Outcomes

Primary Outcomes

To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection

Time frame: 17 days

Secondary Outcomes

Pharmacokinetics in study patients

Time frame: 4 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.